Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT04304079 Withdrawn - Prostate Cancer Clinical Trials

A Novel Augmented Reality System (ARssist) for the Assistant Surgeon in Robotic Assisted Surgery

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Robotic prostatectomy is a surgery for treating localized prostate cancer. The ARssist system is a novel augmented reality system designed for the assistant surgeon, allowing delivery of augmented reality information via Microsoft HoloLens 2 (a head mount display developed by Microsoft) to better delineate the 3-D operative environment and enable better visualization. To date, there is no prospective study on the clinical performance and utilization of the ARssist system. This study is to evaluate the clinical feasibility and safety of the ARssist system during robotic surgery with the da Vinci Xi system.

NCT ID: NCT04296578 Withdrawn - Prostate Cancer Clinical Trials

Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone

Start date: October 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to access the safety of combining sodium selenite with abiraterone and to see what doses of sodium selenite can be safely combined with abiraterone in treating castration resistant prostate cancer.

NCT ID: NCT04272645 Withdrawn - Prostate Cancer Clinical Trials

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Start date: October 2020
Phase: Phase 2
Study type: Interventional

This research is studying two experimental drugs, abemaciclib and atezolizumab, alone and in combination with each other, to learn about the safety and effectiveness of these treatments and their side effects. This is an investigational study treatment for adult men with metastatic castrate resistant prostate cancer (mCRPC) who have progressive disease despite previous treatment with androgen deprivation therapy (ADT). One group of men (men without a genetic mutation called "CDK12 loss") will receive abemaciclib therapy alone. Two other groups of men (men with CDK12 loss in one group and men without CDK12 loss in the other) will receive the combination of abemaciclib and atezolizumab. Another group of men with CDK12 loss will receive atezolizumab therapy alone.

NCT ID: NCT04243941 Withdrawn - Prostate Cancer Clinical Trials

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

Start date: November 29, 2022
Phase: Phase 2
Study type: Interventional

The goal of this study is to determine the safety of using PSMA-PET/mpMRI to define radiotherapy targets, while meeting all current planning criteria. This study also intends to determine the feasibility of performing stereotactic body radiation therapy with simultaneous integrated boost on the dominant intra-prostatic lesions while meeting all current planning criteria.

NCT ID: NCT04027270 Withdrawn - Prostate Cancer Clinical Trials

Pelvic Health and Physical Therapy to Improve Lives of Prostate Cancer Patients Undergoing Prostatectomy

Start date: January 2021
Phase: N/A
Study type: Interventional

Patients will be randomized into standard of care or receiving pre and post operative physical therapy intervention following prostatectomy. Outcome measures will be gathered to assess impact of physical therapy on function and quality of life.

NCT ID: NCT03987568 Withdrawn - Prostate Cancer Clinical Trials

Characterize Tumor Hypoxia by Magnetic Resonance Imaging

Start date: July 10, 2019
Phase: N/A
Study type: Interventional

The purpose of this research study is to measure the hypoxia (low oxygen condition) in prostate cancers and its effect in survival. In this study, investigators will assess hypoxia by magnetic resonance imaging (MRI) and create a hypoxia score. Investigators will study the hypoxia score and how it correlates (if any) to the disease aggressiveness as well as its effect on the treatment outcomes.

NCT ID: NCT03970863 Withdrawn - Prostate Cancer Clinical Trials

Focal Therapy for Localized Prostate Cancer

Start date: August 1, 2020
Phase:
Study type: Observational

To evaluate the cancer control for prostate cancer patients treated with focal therapy.

NCT ID: NCT03909893 Withdrawn - Prostate Cancer Clinical Trials

A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer

ARTGU
Start date: October 2023
Phase: N/A
Study type: Interventional

Radical radiation therapy for prostate cancer is a common treatment that has shown to improve clinical outcomes in a post-operative setting. However, radiation therapy after surgery poses a greater risk for bladder and rectum injury for patients with prostate or bladder cancer. For prostate cancer patients, the risk is further amplified when pelvic nodes are part of the target irradiated volume. For bladder cancer patients, the risk of injury increases when more of the bladder is part of the target volume. Using an adaptive radiation therapy approach allows for correcting any shifts in the target volume. ART approach uses images from treatment to adapt the treatment plan. This study will use Adaptive Radiation Therapy for patients who receive pelvic nodal radiotherapy for either prostate or bladder cancer. Their treatment plans will adapted using MRI scans and CBCT scans taken during their first week of radiotherapy to account for any shifts in the target volume. The purpose of this study is to evaluate the feasibility of ART approach and its and on treatment plan quality metrics for pelvic radiotherapy. Acute and late toxicities will also be evaluated. 40 participants (minimum of 10 bladder cancer patients) will be enrolled. The participants will be followed for a period of 5 years post radiation therapy, during which they will have PSA as per standard practice, along with follow-up questionnaires (EPIC for prostate cancer patients and BUSS for bladder cancer patients).

NCT ID: NCT03823001 Withdrawn - Prostate Cancer Clinical Trials

Virtual Prostate Biopsy Protocol for Patients on Active Surveillance and at Risk of Prostate Cancer

Start date: October 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the use of MRI surveillance for patients with no prostate cancer, potential prostate cancer, or diagnosed low-grade prostate cancer.

NCT ID: NCT03817216 Withdrawn - Prostate Cancer Clinical Trials

Prostatic Urethral Lift (PUL) Pre-/Post-Radiation Treatment for Prostate Cancer

Start date: December 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to test the use of the Prostatic Urethral Lift (PUL), Urolift®, in prostate cancer (Pca) participants seeking or undergoing radiotherapy for relief of urinary obstructive symptoms.